Arovella Therapeutics (ASX:ALA) said a second clinical batch of ALA-101, its cell therapy for blood cancers, has been manufactured and released, according to a Wednesday filing on the Australian bourse.
The company added that a third batch, which it expects to release by the end of December, is anticipated to provide enough material to complete the phase 1 trial of 46 patients across five hospital sites.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.